Predicting Chemotherapy Cardiotoxicity:.

Administering trastuzumab after a course of anthracycline therapy for breast cancer can result in cardiac toxicity. Serial echocardiograms in this study showed that a lower initial left ventricular ejection fraction before anthracycline therapy and the amount of decrease in ejection fraction after the anthracycline course are predictive of subsequent trastuzumab cardiac toxicity. [ABSTRACT FROM AUTHOR]